what is the level of dystrophin expression required for effective therapy of duchenne muscular dystrophy?

Duchenne muscular dystrophy (dmd) is a fatal x-linked muscle wasting disease. the disease is due to mutations in the dmd gene that encodes for a large intracellular protein called dystrophin. dystrophin plays a critical role in linking the internal cytoskeleton of the striated muscle cell with the extracellular matrix as well as having cell signalling functions. in its absence muscle contraction is associated with cycles of damage, repair, inflammation and fibrosis with eventual loss of muscle and replacement with fat. experiments in animal models of dmd have generated a number of different approaches to the induction of dystrophin including viral vector mediated delivery of a recombinant dystrophin gene, antisense oligonucleotide mediated exon-skipping to restore the open reading frame in the dystrophin mrna, read-through of premature stop mutations, genome modification using crispr-cas9 or cell based transfer of a functional dystrophin gene. in all cases, it will be important to understand how much dystrophin expression is required for a clinically effective therapy and this review examines the data from humans and animal models to estimate the percentage of endogenous dystrophin that is likely to have significant clinical benefit. while there are a number of important caveats to consider, including the appropriate outcome measures, this review suggests that approximately 20% of endogenous levels uniformly distributed within the skeletal muscles and the heart be sufficient to largely prevent disease progression.